Pfenex Gets US Teriparatide Nod
Partner Alvogen is expected to launch the Forteo rival upon an FDA equivalence decision
Pfenex’ PF708 version of Forteo, submitted under the US 505(b)(2) hybrid regulatory pathway, has been approved by the FDA. Marketing partner Alvogen is expected to launch as soon as the FDA decides on the product’s equivalence rating after Pfenex submits a key study.
